Diurnal Share Discussion Threads

[tburns] 25/2/2021 10:47

Thanks for that Simon_64 - We know the decision is due by the end of Q1 so 5 weeks max and NO regulation authority to date has denied approval for Chronocort and I do not see the EU bucking that trend now with all the data and peer reviews already assessed by global agencies.

Currency the market is bizarrely allowing you to buy £ notes for circa 40p, that is the discount I am applying here,

[simon_64] 25/2/2021 10:42

tburns

Totally agree with you.

Once the seller runs out people will find it very difficult to buy in anyway worthwhile quantity and with Chronocort around the corner there will be a flurry of announcements, everyone buying at these prices will be grinning from ear to ear in the next 4-6 weeks.

[aimmafia] 25/2/2021 10:41

I've taken more today

[tburns] 25/2/2021 10:33

Just added 25k but had to get them in two bites, couldn't get a price for one trade. That's my bit for the day. GLA

[tburns] 25/2/2021 09:58

Topping up at this level, crazy valuation compared to broker note, only currently 25% of their valuation with EU approval for Chronocort pending

[tarlok] 25/2/2021 09:37

here is the link.....out at 7.15 this morning

[trotterstrading] 25/2/2021 09:35

What is the Hardman price target? £2.14? Seems an odd number

[mikeh30] 25/2/2021 09:15

Final flush. (Remember AGL at 40)

[tarlok] 25/2/2021 09:13

Lots of big sells now....maybe a clear out?

[archie61] 25/2/2021 09:11

Probably sensible waiting for 50p now, falling knife.

[tarlok] 25/2/2021 08:43

HARDMAN research out today price target £2.14.....yeh right ..MM dont agree

[aimmafia] 25/2/2021 08:35

Top up time

[tarlok] 25/2/2021 08:34

And now we know why...this is getting worrying drop now....

[tarlok] 25/2/2021 07:47

So a seller wants out at 55.5p ...33928 sold yesterday...such a shame...so sad

[best1467] 25/2/2021 07:27

Longterm if you read for post it’s slightly odd not sure if it’s Prescriptive text Scenario.
Alkindi and Chronocort are both by Pharma terms small markets but this in my View an advantages lack of completion less hurdles to approvals.
Should Dnl achieve the percentage share around the globe with both these products then a 80 million Mcap is Bargain territory and when you bare in mind the speed of which countries have approved ALK the opinion must be it’s a much needed and improved option to what’s currently available.
Dnl have all so been recognised as the Gold standard in this particular area Ref publications in Prestigious journals plus awards at 2020 Endocrinology summit for achievements in this field so on the balance of probabilities it looks positive

[l0ngterm] 24/2/2021 22:45

What did they pay for the region?

[royalalbert] 24/2/2021 22:26

But Eton have taken on Canada, in my view that would not have happened if the USA was a relative dead duck.

[l0ngterm] 24/2/2021 22:12

The contrarian perspective. If Eton doesn't prove that alkindi can sell then this is a dead horse. No market, no deal. Every deal so far has not lit up the market e.g. 1/2 a million down and 12 million for china (for a 1 billion dollar market?) , not exactly setting the fire on light here, especially if based upon most licensing agreements in pharma.

[aimmafia] 24/2/2021 15:57

To be fair it's all about end of March

[tburns] 24/2/2021 15:28

That doesn't bode too well Aim

[aimmafia] 24/2/2021 11:48

Cannot get a quote for even 1000 shares to sell.

[tarlok] 24/2/2021 09:45

Actually those 10000 trades were buys when ask was being offer at 58.24 /58.25...ask now 58.45...